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Abstract
Background: Breast cancers that harbor mismatch-repair (MMR) deficiency and/or microsatellite instability (MSI) might be
sensitive to immune checkpoint blockade, but there are currently no specific guidelines for assessing MMR status in breast
cancer. Here, we sought to define the clinical value of MMR immunohistochemistry (IHC) and MSI analysis in breast cancers.
Methods: We subjected 444 breast cancers to MMR IHC and MSI analysis. Cases were classified as MMR-proficient (pMMR),
MMR-deficient (dMMR), and MMR-heterogeneous (hMMR) based on the loss of immunoreactivity; MSI was defined by instabil-
ity in the five indicators recommended by the National Cancer Institute for endometrial and colorectal cancers. Correlation of
MMR status with patients’ survival was assessed using the Kaplan-Meier estimator. Statistical tests were two-sided.
Results: Loss of MMR proteins was homogeneous (dMMR) in 75 patients (17%) and heterogeneous (hMMR) in 55 (12%). Among
luminal breast cancers, there were similar frequencies of dMMR and hMMR tumors. Overall, the rate of discrepancy between
IHC and MSI analysis was high (91%). Women with Luminal B-like dMMR carcinomas (n¼44) showed shorter overall survival
(median¼77 months, range¼0–115 months) than those with pMMR (n¼205) or hMMR (n¼35) tumors (median¼84 months,
range¼0–127 months) (P¼ .008). On the contrary, patients with estrogen receptor-negative breast cancers treated with chemo-
therapy lived longer in cases of dMMR (n¼9) than pMMR (n¼33) or hMMR (n¼7) tumors, with 87 months of median survival
(range¼73–123 months) for the former compared with 79 months (range¼8–113 months) for the latter two categories (P< .001).
Conclusions: Immunohistochemistry and MSI are not interchangeable tests in breast carcinomas. MMR protein loss is a more
common event than MSI and shows intra-tumor heterogeneity. MMR IHC allows the identification of clinically relevant sub-
classes of breast cancer patients, provided that multiple areas of the tumor are analyzed.
Mismatch repair (MMR) is a crucial biological system for the rec-
ognition and correction of base mispairs generated during DNA
replication and recombination (1). Four proteins are the main
components of this complex: mutL homolog 1 (MLH1), mutS ho-
molog 2 (MSH2), mutS homolog 6 (MSH6), and postmeiotic seg-
regation increased 2 (PMS2) (1,2). Mutations in MLH1, MSH2,
MSH6, and PMS2 and/or the epigenetic silencing of MLH1 or
MSH2 genes can trigger MMR malfunction, which induces ge-
nome instability and promotes cancer (2,3). Recognition of
MMR-deficient (dMMR) neoplasms is becoming more and more
important (2,4–6). In 2017, the US Food and Drug Administration
approved second-line pembrolizumab —a drug targeting the
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immune-checkpoint programmed cell death protein 1— in any
tumor, thus including breast cancer, showing MMR deficiency
and/or high levels of microsatellite instability (MSI-H) (7). This is
the first time that an international public health agency has ap-
proved a cancer treatment based on biomarkers rather than tu-
mor site or histology (8). Regrettably, the identification of
patients with dMMR cancers is currently based on vastly hetero-
geneous, locally developed laboratory tests.
Although MMR alterations are driver events in a subset of
breast cancers (6,9), their identification is not routine in breast
pathology. Clinical and histopathologic criteria associated with
immunohistochemistry (IHC), polymerase chain reaction-based
testing of microsatellite loci, and sequencing methylation
assays are common practice in the diagnosis of MMR deficiency
(3,10–12). These tools are also widely adopted in translational
research studies for identifying dMMR breast cancers (6,9,13). It
should be noted, however, that the analytical criteria for MMR
IHC and microsatellite instability (MSI) have been adapted from
those tumors where MMR defects are frequently inherited, such
as colorectal and endometrial cancers (5,10,14,15). To date, there
are no validated methods for the assessment of MMR status in
breast cancers. Hence, the overall response rate to pembrolizu-
mab in unselected patients with advanced triple-negative (ie,
estrogen receptor [ER]-, progesterone receptor [PR]-, and HER2-
negative) breast cancers (TNBCs) was 18.5% in a multicenter,
nonrandomized phase Ib clinical trial (16). Furthermore, even
though they represent the vast majority of cases, only a few
data on response to immune checkpoint blockade in ERþ breast
cancers are available to date. In this scenario, the identification
of subpopulations of breast cancer patients that could be more
sensitive to immunotherapy is clinically relevant.
Our study aims to evaluate the clinical value of MMR testing
in breast cancers. Here, we characterized the MMR status in a
large series of breast cancers to define 1) the frequency and clin-
icopathologic features of dMMR breast cancers, 2) the concor-
dance and interchangeability of IHC and MSI analysis for these
patients, 3) the impact of intra-tumor heterogeneity, and 4) the
prognostic and predictive role of MMR defects in breast cancers.
Methods
Patients and Tissue Specimens
A total of 444 breast cancers (2004–2017) were retrieved from the
pathology archives of IRCCS Ca’ Granda Foundation – Policlinico
Maggiore Hospital, Milan, Italy. Only patients diagnosed and
managed in this institution whose tumors were greater than
5 mm in size and for which all histologic slides and blocks were
available for review, as well as detailed clinical and follow-up
data, were included. Patients with previous diagnosis of breast,
gynecological, and colorectal malignancies, with a family his-
tory of breast cancer, fulfilling the Revised Bethesda Guidelines
for the identification of individuals at risk for Lynch syndrome
(including MLH1 IHC-negative MSI-H tumors showing no meth-
ylation of the MLH1 promoter) (9,17), or who received neoadju-
vant therapy were excluded. Samples were anonymized prior to
analysis and the study was approved by the local institutional
review board. All cases were reclassified and graded following
the latest World Health Organization criteria (18) and the
Nottingham grading system (19), respectively. Pathologic restag-
ing was performed according to the eighth edition of the AJCC
Cancer Staging Manual (20). Breast cancer intrinsic molecular
subtypes were determined by ER, PR, Ki67, and HER2 status
following the 2017 St Gallen International Expert Consensus rec-
ommendations (21). All clinicopathologic features and treat-
ment information are summarized in Table 1.
Tissue Microarrays (TMAs) Construction
For each case, samples from the tumor core, invasive front, in
situ component, and non-neoplastic glandular breast tissue
were incorporated into 15 TMAs optimized for the high-
throughput analysis of different topographic areas in large
cohorts of heterogeneously processed breast tumors, as previ-
ously described (22). Each TMA block contained up to 180 tumor
cores measuring 2 mm in diameter, with a total number of 2790
spots of tissue (mean of 5.8 tumor tissue cores per case,
range¼ 2–7 cores).
Immunohistochemical Analysis
Representative 4-lm-thick sections were cut from the TMA
blocks and subjected to IHC using prediluted antibodies against
ER, PR, Ki67, HER2, MLH1, MSH2, MSH6, and PMS2. Positive and
negative controls were included in each slide run. Briefly, the
protocols use two automated staining systems (ie, Dako Omnis
and Ventana Benchmark Ultra) and anti-human prediluted
antibodies (23). Protein expression was analyzed separately in
all morphologically different tumor components by two inde-
pendent pathologists (NF and GL) (24). Discordant results were
resolved during dedicated consensus sessions. The methods
and scoring systems employed followed previously reported cri-
teria and guidelines (10,25–28), as detailed in Supplementary
Table 1 (available online). Specifically, loss of MMR protein ex-
pression was defined by the complete absence of nuclear stain-
ing within all neoplastic cells (15). Cancers showing retained
protein expression of the four MMR proteins across the entire
tumor were defined as MMR-proficient (pMMR), and the diffuse
loss of one or more MMR proteins designated the dMMR status.
When the protein was expressed in only a part of the tumor (ie,
<50% of tumor cells within 1 tissue core, as shown in
Supplementary Figure S1, available online), the case was
recorded as MMR-heterogeneous (hMMR). Whole tissue tumor
sections from all dMMR and 25 pMMR cases were subjected to
MMR IHC to confirm their non-hMMR phenotype.
Silver in Situ Hybridization
Three-lm-thick sections from all TMAs underwent silver in situ
hybridization using probes for HER2 and its corresponding
centromere (CEP17) and were assessed according to the
American Society of Clinical Oncology (ASCO)/College of
American Pathologists (CAP) recommendations (26), as detailed
elsewhere (22).
Cancer Cell Enrichment and DNA Extraction
Tumor and matched normal breast tissues of all hMMR and
dMMR cases were manually microdissected using a sterile nee-
dle under a stereomicroscope (Stemi 305, Zeiss, Germany) to en-
sure more than 85% of tumor cell content and that the normal
tissue was devoid of atypical cells (29). Microdissection was per-
formed by two of the authors (GL and CC) under the supervision
of a breast pathologist (NF). Genomic DNA extraction was per-
formed as described (30).
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Microsatellite Instability Analysis
All dMMR breast cancers and matched normal tissues were
subjected to MSI testing using the five indicators recom-
mended by the National Cancer Institute (31), which included
two quasimonomorphic mononucleotides (BAT25 and BAT26)
and three polymorphic dinucleotides (D2S123, D5S346, and
D17S250). The polymerase chain reaction primer sequences
are listed in Supplementary Table 2 (available online). The
analysis was performed by capillary gel electrophoresis using
the Gene Mapper software on an ABI 3130XL system (Applied
Biosystems, Foster City, CA). Tumors were considered MSI-
positive when alterations appeared in the microsatellite
profiles of the tumor sample (ie, mismatch in >1 major electro-
pherogram peaks compared to the non-neoplastic counter-
part) (31). Low-frequency MSI and MSI-H were defined by the
presence of one and two or more unstable markers, respec-
tively (5,10,28).
Statistical Analyses
Differences in MMR proteins expression across tumor types
were investigated using the v2 test (IBM SPSS). To assess the cor-
relation between the clinicopathologic features and MMR pro-
tein loss, nonparametric models were applied first using the
MMR status of each case in a dual fashion (pMMR/dMMR). A sec-
ond proportional-hazards regression analysis taking into ac-
count the hMMR status was subsequently performed.
Correlation of the protein’s patterns of expression to patients’
overall and disease-free survival was assessed using the
Kaplan-Meier estimator. Patients who died from causes other
than breast cancer (n¼ 10) were labeled as censored at death for
survival analysis. Quantitative analyses were performed using
the multiple Cox proportional hazards regression to assess the
independence of MMR IHC as a prognostic factor (32). Two-sided
probability values (P) less than .05 were considered statistically
significant.
Table 1. Clinicopathologic features and treatment information of the patients included in the study
Therapy
Characteristic No. of patients (%) HT (%) CT (%) TTZ (%) RT (%) None (%)
All patients 444 259 (58) 190 (43) 13 (3) 300 (68) 8 (2)
Age at diagnosis, y
55 311 (60) 204 (66) 104 (33) 10 (3) 221 (71) 7 (2)
<55 133 (30) 55 (41) 86 (65) 3 (2) 79 (59) 1 (1)
T status
pT1 262 (59) 147 (56) 106 (41) 3 (1) 208 (79) 6 (2)
pT2 147 (33) 98 (67) 62 (42) 8 (5) 82 (56) 2 (1)
pT3–4 35 (8) 14 (40) 22 (63) 2 (6) 10 (29) 0
N status
pN0 257 (58) 169 (66) 71 (28) 4 (2) 195 (76) 7 (3)
pN1–3 187 (42) 90 (48) 119 (64) 9 (5) 105 (56) 1 (1)
Histological grade
1 46 (10) 26 (57) 12 (26) 0 38 (83) 3 (7)
2 190 (43) 130 (68) 56 (30) 1 (1) 132 (70) 3 (2)
3 208 (47) 103 (50) 122 (59) 12 (6) 130 (63) 2 (1)
Hormone receptor status
Positive 392 (88) 259 (66) 145 (37) 9 (2) 271 (69) 4 (1)
Negative 53 (12) 0 45 (85) 4 (8) 29 (55) 4 (9)
HER2 status
Positive 81 (18) 47 (58) 41 (51) 13 (16) 52 (64) 1 (1)
Negative 363 (82) 212 (58) 149 (41) 0 248 (68) 7 (2)
Ki67 status
High 302 (68) 163 (54) 155 (51) 13 (4) 195 (65) 6 (2)
Low 142 (32) 96 (68) 35 (25) 0 105 (74) 2 (1)
Histological subtype
Invasive carcinoma, NST 344 (77) 193 (56) 160 (47) 11 (3) 230 (67) 4 (1)
Lobular 53 (12) 39 (74) 13 (25) 1 (2) 40 (76) 1 (2)
Other 47 (11) 27 (58) 17 (36) 1 (2) 30 (64) 3 (6)
Intrinsic molecular subtype
Luminal A-like* 108 (24) 76 (70) 28 (26) 0 81 (75) 1 (1)
Luminal B-like (HER2þ)† 73 (16) 47 (64) 34 (47) 9 (12) 49 (67) 1 (1)
Luminal B-like (HER2-)‡ 211 (48) 136 (65) 84 (40) 0 142 (67) 3 (1)
HER2-type§ 8 (2) 0 7 (88) 4 (50) 3 (38) 0
TNBCk 44 (10) 0 37 (84) 0 25 (57) 3 (7)
*ERþ/PRþ/Ki67 low. All cases were reclassified, regraded, and reassessed for hormone receptor, Ki67, and HER2 status according the latest guidelines (18–20).
Treatment data refer to the therapy performed using the different clinical protocols and guidelines during the follow-up period (2004–2017). NST¼no special type;
HT¼hormone therapy; CT¼ chemotherapy; TTZ¼ trastuzumab; RT¼ radiotherapy; TNBC¼ triple-negative breast cancer.
†ERþ/PRþ/HER2þ/Ki67 high or ERþ/PR/HER2þ.
‡ERþ/PRþ/HER2/Ki67 high or ERþ/PR/HER2.
§ER/PR/HER2þ.
kER/PR/HER2.
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Results
Mismatch Repair Protein Expression and Intra-Tumor
Heterogeneity
Among the 444 breast cancers analyzed, 41 (9%), 55 (12%), 24
(10%), and 21 (5%) cases showed homogeneous loss of MLH1,
MSH2, MSH6, and PMS2, respectively, and the cases showing
intra-tumor heterogeneity ranged from 7 (1%) for PMS2 to 42
(10%) for MSH2 (Supplementary Table 3, available online). The
relative frequency of heterogeneous protein expression ranged
from 33% for PMS2 to 50% for MSH6, with higher rates in
Luminal cancers, as depicted by the black bars in
Supplementary Table 3 (available online). Taken together, 314
(71%) breast cancers were pMMR and 75 (17%) and 55 (12%)
tumors were dMMR and hMMR, respectively (Figure 1). The
prevalence of carcinomas showing loss of MMR proteins across
the intrinsic molecular subtypes ranged from 15% to 21% for
dMMR (mean 16.8%) and 9% to 25% for hMMR (mean 15.1%), as
shown in Figure 1 and Supplementary Tables 3 and 4 (available
online). No hMMR tumors were observed in pT3–4 Luminal A-
like and Luminal B-like (HER2þ) tumors or in pT2–4 TNBCs.
Among the other pathologic (p)T and pN categories, the preva-
lence of hMMR tumors ranged from 7% to 50% (Supplementary
Figure 2, available online). These findings suggest that the MMR
protein analysis in a single area of the tumor may not represent
the MMR status of the entire breast neoplasm.
Microsatellite Instability in Breast Cancers with MMR
Protein Loss
All 75 dMMR tumors were analyzed for MSI using the widely
adopted combination of mono- and dinucleotide markers
(31,33). Ten hMMR cases with a protein loss comprising more
than 85% of the tumor were also analyzed. Among breast
cancers belonging to the dMMR category, 68 (91%) tumors were
microsatellite-stable, as shown in Figure 2 and Table 2. None of
the hMMR breast cancers showed MSI, akin to pMMR tumors.
Furthermore, 6/7 (86%) dMMR tumors (#40, #67, #82, #95, #113,
and #148) harbored instability in only one locus and were de-
fined as low-frequency MSI, whereas only 1 tumor (#186) was
MSI-H (Figure 2; Table 2; Supplementary Figure 3;
Supplementary Table 4, available online). No BAT26- and
D5S346-unstable breast cancers were observed (Supplementary
Figure 3, available online). The low level of overlap between IHC
and MSI analysis (1% if considered MSI-H tumors) suggests that
the five markers recommended by the National Cancer Institute
may underestimate the actual MMR status in breast cancer.
The Prognostic and Likely Predictive Role of MMR
Deficiency in Breast Cancers
Survival analysis showed different overall survival rates be-
tween dMMR and non-dMMR breast cancer patients. Among
Luminal B-like carcinomas, patients with pMMR (n¼ 205) and
hMMR (n¼ 35) tumors lived longer than those with dMMR
(n¼ 44) cancers (P¼ .008), as depicted in Figure 3A. Specifically,
8 of 240 (3.3%) patients with pMMR or hMMR cancers died of dis-
ease after 0–127 (median¼ 84) months, while 6 (13.6%) of
patients with dMMR tumors died after 0–115 (median¼ 77)
months. The prognostic role of MMR deficiency was maintained
in chemotherapy-naı¨ve (n¼ 166, P¼ .003) but not in
chemotherapy-treated (n¼ 118, P¼ .181) patients. Of note, both
the risks of death and recurrence were similar among women
with pMMR and hMMR breast cancers irrespective of the clinico-
pathologic and molecular characteristics (P> .05). Interestingly,
survival analyses of HER2-type and TNBC patients based on
MMR system activation showed a completely different scenario
(Figure 3B). Taking together the ER-negative patients, whose
clinicopathologic features are detailed in Supplementary Table
Figure 1. Mismatch repair status of 444 sporadic breast cancers according to the intrinsic molecular subtypes. Bar graph showing the uniform relative proportion of
mismatch repair deficient (dMMR), heterogeneous (hMMR), and proficient (pMMR) breast cancers across the intrinsic molecular subtypes. The three immunohisto-
chemical scenarios are color-coded on the basis of the legend on the bottom left.
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4 (available online), dMMR tumors (n¼ 9) showed a better prog-
nosis both in terms of overall and disease-free survival com-
pared with pMMR (n¼ 33) and hMMR (n¼ 7) neoplasms
(P< .001), with 87 months of median survival (range¼ 73–
123 months) for the former compared with 79 months
(range¼ 8–113 months) for the latter two categories (P< .001). All
of these patients underwent first-line chemotherapy. On the
contrary, the MMR status did not affect the prognosis of
Luminal A-like tumors. No statistically significant correlations
between MMR deficiency and clinicopathologic features were
observed. The number of MMR proteins showing IHC loss was
not associated with statistically significant increased risks of
death and/or recurrence in any subgroup of patients.
Clinicopathologic Features of MMR-Deficient Breast
Cancers
The median age at diagnosis of the 75 patients with dMMR
breast cancer was 65 years (range¼ 31–85 years), higher than in
pMMR patients (Table 3). Most dMMR breast cancers were inva-
sive ductal carcinomas of no special type (79%) and encom-
passed 21 (28%) Luminal A-like, 44 (59%) Luminal B-like, 1 (1%)
HER2-type, and 9 (12%) TNBCs (Figure 2; Table 3). Thirty-four
(45%) dMMR tumors harbored complete loss of expression of
one protein, while in 24 (32%) and 8 (11%) cancers the loss in-
volved protein pairs and triplets, respectively (Figure 2; Table 2).
Of note, 9 (12%) tumors displayed uniform loss of all four MMR
proteins. Taken together, no specific patterns of MMR protein
loss were observed across dMMR breast cancers. Forty-one
(55%) carcinomas harbored homogeneous loss of MLH1, 55 (73%)
of MSH2, 24 (32%) of MSH6, and 21 (28%) PMS2 (Table 2). The lat-
ter was the most stable MMR protein in the tumor samples,
showing heterogeneous expression in only three cases, as con-
firmed by the analysis of full sections. The highest level of
intra-tumor heterogeneity in MMR protein expression was ob-
served for MSH6.
Discussion
Our study documents the clinical impact of MMR testing in a
large series of breast cancers by means of the most commonly
adopted diagnostic tools and criteria. We show that MMR pro-
tein loss is a rather common event in breast cancer and shows a
remarkable degree of intra-tumor heterogeneity, therefore mak-
ing the analysis of a small area of the tumor, or a small biopsy,
of little clinical value. Our investigation supports the concept
that MSI occurs rarely in breast cancer (9) and demonstrates
that this condition is restricted to a minority of tumors with
MMR protein loss. These data suggest that MMR IHC and MSI
analysis should not be considered as interchangeable tests in
the diagnostic workup of breast carcinomas. Finally, our obser-
vations indicate that the complete loss of at least one of the
MMR proteins assessed by IHC is able to identify high-risk
Luminal breast cancers that might potentially benefit from
pembrolizumab therapy, whereas first-line chemotherapy
shows comparatively good results in dMMR TNBCs.
The histology-agnostic approval of the monoclonal antibody
pembrolizumab by the US Food and Drug Administration in all
dMMR and/or MSI-H tumors (7) opened new avenues for the
clinical management of breast cancer patients. This
Figure 2. Overview of 75 mismatch repair deficient breast carcinomas. Heatmap illustrating the clinical, histologic, and biological information together with mismatch
repair protein status and microsatellite instability data of all mismatch repair-deficient cases identified. Each column represents a case, each row a parameter, which
is color-coded according to the legend below. ER¼estrogen receptor; IHC¼ immunohistochemistry; MSI¼microsatellite instability; MSI-H¼microsatellite instability
high; MSI-L¼microsatellite instability low.
Table 2. MMR and microsatellites alterations frequency in dMMR
breast cancers*
Characteristic No. of patients (%)
dMMR patients 75
MLH1
Retained 28 (37)
Heterogeneous 6 (8)
Loss 41 (55)
MSH2
Retained 12 (16)
Heterogeneous 8 (11)
Loss 55 (73)
MSH6
Retained 38 (51)
Heterogeneous 13 (17)
Loss 24 (32)
PMS2
Retained 51 (68)
Heterogeneous 3 (4)
Loss 21 (28)
No. of MMR markers with IHC loss
1 34 (45)
2 24 (32)
3 8 (11)
4 9 (12)
Microsatellite instability
High 1 (1)
Low 6 (8)
Negative 68 (91)
*dMMR¼mismatch repair deficient; IHC¼ immunohistochemistry;
MLH1¼mutL homolog 1; MMR¼mismatch repair; MSH2¼mutS homolog 2;
MSH6¼MSH2¼mutS homolog 6; PMS2¼postmeiotic segregation increased 2.
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unprecedented decision, however, was based on 149 patients
with MSI-H or dMMR cancers enrolled in five single-group clini-
cal trials (8). Most of these patients (84%) had colorectal cancer,
whereas only a few of them had breast cancer. Given the cur-
rent focus on precision immuno-oncology, tumor-specific com-
panion diagnostic tests are warranted (34). Because breast
cancer is the most frequent malignant tumor in women (35),
the implementation of a reliable MMR diagnostic strategy would
be potentially beneficial in identifying patients eligible for
immune-checkpoint blockade. For this reason, we decided to
apply to breast cancer the widely-employed diagnostic algo-
rithms for MMR status assessment and characterize their clini-
cal consistency.
To our knowledge, this is the first study aiming to define the
clinical consequences of intra-tumor heterogeneity in breast
cancer MMR testing. Hence, intra-tumor heterogeneity is a ma-
jor problem in biomarkers assessment for making decisions
about treatment, particularly on small tissue samples (eg, core
biopsies) (36–38). In this study, we have provided novel evidence
that the MMR proteins are heterogeneously expressed in more
than 12% of breast cancers, with no preferential distribution in-
side the tumor. The therapeutic implications of intra-tumor
heterogeneity of the MMR phenotype are yet to be ascertained
and require dedicated clinical prospective studies. Conversely,
the possibility of heterogeneous MLH1, MSH2, MSH6, and PMS2
distribution should be considered while performing MMR test-
ing. Our findings suggest that MMR analysis by IHC in breast
cancer requires an extensive sampling of the lesion in surgical
resections and should be performed on multiple, possibly all,
tumor blocks. The intrinsically low sensitivity of this test in bio-
ptic samples should be taken into account in unresectable ad-
vanced tumors and in presurgical samples for neoadjuvant
studies.
Massively parallel sequencing studies have demonstrated
that approximately 4% of breast cancers harbor MMR alterations
in the tumor cells, as confirmed by public genomic data (9,39–
42). Our analysis of 444 breast cancers documented a higher
proportion of dMMR tumors, where 17% of carcinomas showed
complete IHC loss of at least one MMR protein in all neoplastic
areas. Interestingly, the condition of MMR deficiency is not re-
lated to the histological and/or molecular type. Furthermore, in
contrast to endometrial and colorectal cancer, an exceedingly
small proportion of dMMR tumors were found to be microsatel-
lite unstable, whereas only one case was MSI-H using the five
standard MSI markers. Many seminal works aimed to investi-
gate the usefulness of MSI analysis in breast cancer, with con-
flicting results. Taken together, more than 300 different
Figure 3. Overall survival of the patients included in the study for selected tumor characteristics on the basis of mismatch repair status. A) Probability of death in
Luminal B-like breast cancer patients with mismatch repair deficient (dMMR, red) tumors, patients with mismatch repair proficient (pMMR, light blue), and patients
with mismatch repair heterogeneous (hMMR, orange); median survival of 77 (range¼0–115) months for the former compared with 84 (0–127) months for the latter two
categories. B) Probability of death in chemotherapy-treated hormone receptor negative breast cancer patients with mismatch repair proficient (pMMR, light blue), het-
erogeneous tumors (pMMR/hMMR, dark blue), and mismatch repair deficient tumors (dMMR, red); median survival of 87 (range¼73–123) months for the former com-
pared with 79 (range¼8–113) months for the latter two categories. The curves are built according to the Kaplan-Meier method, P values were calculated using two-
sided Log-rank tests. Numbers at risk appear below the graphs.
Table 3. Clinicopathologic features of dMMR breast cancers com-
pared with pMMR*
dMMR hMMR pMMR
Characteristic (n¼ 75) (n¼ 55) (n¼ 314)
Median age at diagnosis, y 65 60 61
Histological subtype, No. (%)
NST 59 (79) 48 (87) 237 (76)
Lobular 9 (12) 2 (4) 42 (13)
Other 7 (9) 5 (9) 35 (11)
Histological grade, No. (%)
G1 6 (8) 5 (9) 35 (11)
G2 32 (43) 21 (38) 137 (44)
G3 37 (49) 29 (53) 142 (45)
T pathologic staging, No. (%)
pT1 38 (50) 32 (58) 192 (61)
pT2 29 (39) 19 (35) 99 (32)
pT3 2 (3) 1 (2) 7 (2)
pT4 6 (8) 3 (5) 16 (5)
N pathologic staging, No. (n)
pN0 35 (47) 31 (56) 191 (61)
pN1 25 (33) 10 (18) 78 (25)
pN2 10 (13) 11 (20) 21 (7)
pN3 3 (7) 3 (6) 24 (8)
Hormone receptor positive, No. (%) 65 (87) 49 (89) 277 (88)
Ki67 high, No. (%) 43 (57) 37 (67) 222 (71)
HER2-positive, No. (%) 13 (17) 15 (27) 53 (17)
*dMMR¼mismatch repair deficient; ER¼estrogen receptor; NST¼ invasive car-
cinoma of no special type (ductal); pMMR¼mismatch repair proficient (includ-
ing heterogeneous cases); PR¼progesterone receptor.
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microsatellite markers have been tested for MSI assessment in
breast cancer, showing marked variations in terms of detection
rates (43). Although most of these markers have demonstrated
to be largely uninformative, D17S250 has been reported as the
most reliable for its positive predictive value (43). In our series,
however, only one case showed instability in D17S250, confirm-
ing that the choice of microsatellite markers may affect the MSI
detection rate. The conflict between the MSI model in colorectal
and endometrial cancers and that of breast cancer suggests that
not all breast carcinomas harboring defects in DNA repair sys-
tems display high levels of genomic instability, as recently
reported in homologous recombination repair-deficient breast
cancers (44,45). Our study is the first to our knowledge to assess
the clinical reliability of this widely adopted diagnostic platform
in breast malignancies, and the results provide strong evidence
against the interchangeability of IHC and state-of-the-art MSI
analysis in these patients. This represents an additional consid-
eration in patients’ selection for immunotherapy. It remains to
be determined which patients would benefit more from pem-
brolizumab administration between IHC-negative/MSI-positive
and IHC-negative/MSI-negative breast cancers, requiring further
large-scale multicentric studies.
The clinical importance of MMR testing in breast cancers has
implications for the prognostic value of IHC, which is unrelated
to MSI investigation. Spatial heterogeneity analysis of MMR pro-
tein expression revealed similar results in terms of prognosis
between hMMR and pMMR breast cancers. These data suggest
that the partial loss of the MMR proteins does not represent a
detrimental condition for the MMR system in breast cancer, as
also reported in endometrial cancer (14). Here, we have demon-
strated that the overall survival rates of dMMR and non-dMMR
breast cancers are radically different. Interestingly, dMMR
Luminal B-like patients showed a worse prognosis compared
with both pMMR and hMMR, particularly among chemotherapy-
naı¨ve patients. These data suggest that this specific molecular
subgroup of patients could be an appropriate target for
immune-checkpoint inhibition. Clinical trials designed to com-
pare the performance of first-line immunotherapy (alone or in
combination) with the traditional therapeutic approaches in ER-
positive breast cancers would be needed. In contrast to what we
have observed in Luminal B-like tumors, dMMR chemotherapy-
treated ER-negative breast cancers had an excellent outcome
both in terms of disease-free survival and overall survival.
These observations provide circumstantial evidence to suggest
that phenomena of synthetic lethality (4) might improve the ef-
ficacy of chemotherapy in these tumors. Definition of the clini-
cal rationale of pembrolizumab administration in these
patients and whether MMR testing by IHC can be employed as a
biomarker of prognosis and chemotherapy efficacy require vali-
dation in independent cohorts of breast cancer patients.
This study has some limitations. First, we did not analyze
the germ lines of our patients to identify and subsequently ex-
clude syndromic breast cancers. However, the analysis of MLH1
promoter methylation coupled with clinical and family infor-
mation has been shown to represent a rational testing surrogate
for Lynch syndrome, both in the clinic and in breast cancer
translational research studies (9,11,46). Furthermore, we are
aware that the use of TMAs might underestimate the intra-
tumor heterogeneity. To reduce this possible drawback, we
have analyzed full sections of all dMMR tumors. In addition,
next-generation sequencing studies have recently provided evi-
dence to suggest that dMMR tumors exhibit a hypermutator
phenotype, but we did not perform these analyses. Despite
these limitations, we aimed to define for the first time in breast
cancer the reliability of the MMR testing methods currently
employed in clinical practice (ie, IHC and MSI analysis). Further
clinical trials coupled with massively parallel sequencing stud-
ies are needed to assess the role of mutational burden as a pre-
dictive biomarker for immune checkpoint blockade. Finally,
given the relatively small number of tumors analyzed, caution
should be exercised in the interpretation of the clinical impact
of our observations. Hence, this study should be considered
hypothesis generating. Further investigations including larger
cohorts of patients are warranted to elucidate the clinical role of
MMR testing in breast cancer.
Our results indicate that the IHC analysis of multiple areas of
the tumor, regardless of microsatellite status, has a prognostic and
likely predictive role in both Luminal B-like and ER-negative breast
cancers. Further development of reliable testing for MMR in breast
cancer is required to fully understand the prognostic and predictive
role of MMR status, to further select those patients who may bene-
fit from systemic therapy, and to facilitate the rational testing and
use of immunotherapeutics in breast cancer.
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